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ABSTRACT
Background
Early diagnosis and treatment with artesunate-mefloquine combination therapy (MAS) have
reduced the transmission of falciparum malaria dramatically and halted the progression of
mefloquine resistance in camps for displaced persons along the Thai-Burmese border, an area
of low and seasonal transmission of multidrug-resistant Plasmodium falciparum. We extended
the same combination drug strategy to all other communities (estimated population 450,000)
living in five border districts of Tak province in northwestern Thailand.
Methods and Findings
Existing health structures were reinforced. Village volunteers were trained to use rapid
diagnostic tests and to treat positive cases with MAS. Cases of malaria, hospitalizations, and
malaria-related deaths were recorded in the 6 y before, during, and after the Tak Malaria
Initiative (TMI) intervention. Cross-sectional surveys were conducted before and during the TMI
period. P. falciparum malaria cases fell by 34% (95% confidence interval [CI], 33.5–34.4) and
hospitalisations for falciparum malaria fell by 39% (95% CI, 37.0–39.9) during the TMI period,
while hospitalisations for P. vivax malaria remained constant. There were 32 deaths attributed
to malaria during, and 22 after the TMI, a 51.5% (95% CI, 39.0–63.9) reduction compared to the
average of the previous 3 y. Cross-sectional surveys indicated that P. vivax had become the
predominant species in Thai villages, but not in populations living on the Myanmar side of the
border. In the displaced persons population, where the original deployment took place 7 y
before the TMI, the transmission of P. falciparum continued to be suppressed, the incidence of
falciparum malaria remained low, and the in vivo efficacy of the 3-d MAS remained high.
Conclusions
In the remote malarious north western border area of Thailand, the early detection of malaria
by trained village volunteers, using rapid diagnostic tests and treatment with mefloquine-
artesunate was feasible and reduced the morbidity and mortality of multidrug-resistant P.
falciparum.
The Editors’ Summary of this article follows the references.
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The development and spread of multidrug-resistant
Plasmodium falciparum parasites has impaired decades of
efforts to reduce the burden of malaria worldwide. In
Thailand, where the most resistant parasites are found, the
National Malaria Control Programme has successfully re-
duced malaria morbidity and mortality in most of the
country using vector control measures and a large network
of malaria clinics delivering free diagnosis and treatment [1].
Malaria transmission is now limited to the forested and hilly
areas of the Eastern and Western border provinces and the
Southern peninsula. The most affected populations are the
ethnic minorities, displaced persons, and migrant workers,
and the highest incidence is in Tak Province bordering
Myanmar.
The ﬁrst focus of chloroquine resistance in P. falciparum
was described among Thai gem workers returning from
nearby Cambodia in 1957 [2]. Over the subsequent 40 y, P.
falciparum has developed resistance to all antimalarial drugs
except the artemisinin derivatives. In 1985, Thailand became
the ﬁrst country to use meﬂoquine for the treatment of
uncomplicated malaria, but resistance to meﬂoquine devel-
oped rapidly on both the Eastern and the Western borders
[3–5]. In 1991–1992, different regimens of meﬂoquine with
artesunate were tested in trials in Bangkok and in Karen
refugee camps in Tak province [6,7]. This proved to be a
highly effective and safe treatment and by 1994, when the
failure rate of meﬂoquine monotherapy reached 60%, a
combination of 25 mg/kg of meﬂoquine and 12 mg/kg of
artesunate given over 3 d (MAS3) was deployed as ﬁrst-line
treatment in all refugee camps along the Thai-Myanmar
border [8]. MAS3 has remained the treatment of choice since
then. Very large studies have conﬁrmed its safety and
efﬁcacy [9].
The effects of deploying the MAS3 combination on malaria
incidence was analysed among Karen displaced people living
in refugee camps in Tak province from 1986 to 1997. A 6-fold
reduction in P. falciparum malaria incidence was observed,
while the incidence of P. vivax malaria remained stable. This
large reduction was attributed to the combination of early
diagnosis (ED) by microscopy or rapid tests and prompt
treatment using MAS3: meﬂoquine (25 mg/kg) and artesunate
(12 mg/kg) [10].
In order to determine whether similar results (obtained in
the well-controlled environment of camps for displaced
persons) could be obtained in an open setting, a collabo-
rative project between the Thai Ministry of Public Health,
the Faculty of Tropical Medicine, Mahidol University, and
the Shoklo Malaria Research Unit (SMRU, part of the
Wellcome Trust–Mahidol University–Oxford Tropical Med-
icine Research Programme) was developed in the ﬁve border
districts of Tak province (Figure 1). The Tak Malaria
Initiative (TMI) aimed to provide access to ED and treatment
with an artemisinin-based combination therapy (ACT) to all
populations living along the northwestern border with
Myanmar. We report the impact of this intervention on
malaria morbidity and mortality in the targeted area by
comparing epidemiological indicators before (October 1995–
September 2001), during (October 2001–September 2002),
and after (October 2002–September 2003) the TMI inter-
vention.
Methods
Study Area and Populations
Tak province shares over 500 km of border with Myanmar
and is divided into nine districts. The ﬁve districts selected
for the TMI project are composed of rugged, hilly, and mostly
forested terrain: Mae Ramat (MRM), Mae Sot (MS), Phob Phra
(PP), Tha Song Yang (TSY), and Umphang (UMP). The
remaining four districts of the province have virtually no
malaria. The climate is tropical with a 6-mo rainy season
(from May to early October). Mean annual rainfall varies
between 1,400 mm in the southern and central areas and
2,300 mm in the northern district. The mean temperature
ranges from 20.2 8C in December to 29.3 8C in April, and the
annual relative humidity is above 75%.
The population at risk of acquiring malaria and targeted by
the TMI project can be divided into three groups: (1) Thai
citizens (approximately 300,000, of which half are Thai and
the other half belong to ethnic minorities); (2) foreign
nationals (FNs) (approximately 150,000, mainly migrant
workers from Myanmar). The Thai National Ministry of
Welfare and Social Labour provides reliable estimates of the
total annual number of FNs living in the province. It includes
registered workers with work permits, a mainly stable
population estimated at 50,000 annually for the past 5–6 y.
Figure 1. Map of Tak Province
The study area is shown in grey.
DOI: 10.1371/journal.pmed.0030183.g001
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but relatively stable. The remaining FNs are considered
illegal, and are mostly temporary workers; and (3) displaced
persons (65,000 mainly Karen displaced people living in semi-
open camps in TSY, PP, and UMP (Thai Burma Border
Consortium, unpublished data). Health care in the camps is
provided by medical International Non-Governmental Or-
ganizations and food is supplied by a consortium of charities.
Epidemiology of Malaria
Most of the detailed information on entomology, epidemi-
ology, and impact of ACT deployment in this area before the
TMI intervention derives from observations in the camps for
displaced persons [10,11]. The area has a low and unstable
malaria transmission with two seasonal peaks, in June and in
December. The predominant malaria vectors are the forest-
inhabiting mosquito Anopheles dirus, and the forest fringe
mosquitoes An. maculatus and An. minimus. A preference for
outdoor resting and feeding at a time when people are still
active make the malaria vectors difﬁcult to control. P.
falciparum and P. vivax are the predominant species, while the
two other species (P. malariae and P. ovale) are found occasion-
ally. Malaria cases are symptomatic in all age groups [11].
Malaria Control Programme
The Thai National Malaria Control Programme (Malaria
Division) is a vertical programme and functions in the ﬁve
border districts of Tak Province through a network of 37
malaria clinics. Light microscopy of Giemsa-stained thick and
thin blood ﬁlms are used routinely in all malaria clinics for
the diagnosis of malaria. Vector control consists of indoor-
chemical residual spraying (DDT until 1997, then subse-
quently 5% deltamethrin) once or twice a year, and
impregnation of bed nets with 10% permethrin 30 mg/m
2
every 6 mo. Patients with a malaria smear positive for P.
falciparum species at the Malaria Control Programme clinics
are treated with artesunate (Atlantic Company Limited) (6
mg/kg/d for 2 d) together with meﬂoquine (Atlantic Company
Limited) (25 mg/kg) split into two doses and given 6 h apart
(MAS2). This ‘‘shorter’’ regimen was shown recently to be less
effective than the 3-d regimen recommended by the WHO
[12,13], but was chosen on the assumption that adherence will
be improved. In addition, one dose (30 mg) of primaquine
(Governmental Pharmaceutical Organization) is given. In-
fections with P. vivax, P. malariae, or P. ovale are treated with
chloroquine 25 mg base/kg (Governmental Pharmaceutical
Organization) over 3 d, as well as primaquine (15 mg/d for 14
d). Clinically severe or complicated cases, or those with
danger signs, children under 1 y of age, and pregnant women,
are referred to the closest district hospital. In the study area
there are one general hospital (300 beds) in MS and four
community hospitals. In Thailand the private sector plays a
relatively small role in malaria case management and malaria
control and has not been included in this analysis.
In the Karen camps, the control of malaria is done by
medical International Non-Governmental Organizations as-
sisted by SMRU. The Malaria Division provided indoor-
residual spraying in May 1998, March 2000, and April 2001.
The majority of the displaced population uses bed nets
(mostly non-impregnated) provided by the Thai Burma
Border Consortium. The World Health Organization recom-
mended a 3-d regimen of artesunate (4 mg/kg/d) combined
with meﬂoquine (none on the ﬁrst day of treatment, 15 mg/kg
on the second day, and 10 mg/kg on the third day) is used for
the treatment of uncomplicated P. falciparum infections. Its
parasitological efﬁcacy has been monitored continuously by
SMRU and remains above 90% with 63 d follow-up [14].
Severe malaria cases, patients with uncomplicated hyper-
parasitaemia, and pregnant women are all treated in the
camp clinics. Artesunate is used for severe malaria or
uncomplicated hyperparasitaemia. Quinine is used for
malaria in the ﬁrst trimester of pregnancy. Other malaria
species are treated with chloroquine 25 mg base/kg divided
and given over 3 d; primaquine is not routinely used in the
camps because of the lack of evidence of efﬁcacy (except for
the impractical 14-d supervised regimen) and the high
incidence of G6PD deﬁciency (10%) in the population.
Changes Introduced during the Tak Malaria Initiative
(September 2001–October 2002)
The basis of the TMI intervention was to provide ED and
treatment with an ACT to all exposed inhabitants of the ﬁve
border districts. The estimated target population was 450,000
(excluding the refugee population). The people living in
camps (population 65,000) already had access to ED and
treatment with an ACT since 1994, so the efforts concen-
trated on the villages and the population of migrant workers.
In August 2001, 120 medical personnel from the health
centres and health posts received a refresher course in
microscopic diagnosis and were trained to perform rapid
diagnostic tests for malaria (using both Paracheck and
Optimal). All 59 health centres and 33 health posts from
the conventional health system were provided with diagnostic
tools and antimalarial drugs for uncomplicated malaria. In
addition, 100 malaria posts (MPs) were created in villages
where health services were not readily accessible and in
migrant worker settlements (Figure S1). Each MP was under
the responsibility of one malaria worker, a native of the area,
and usually well known and accepted by the villagers
themselves. Five mobile teams were set up to reach more
unstable mobile populations such as migrant workers. Rapid
diagnostic tests (Paracheck-Pf and OptiMAL) were used for
diagnosis in all these new structures, in combination with
microscopy in health centres and mobile teams. More
Paracheck-Pf tests were used during TMI because it is
cheaper (US $0.6 versus US $1.5 per test), but has comparable
sensitivity and speciﬁcity in the detection of P. falciparum.
OptiMAL has the added advantage of detecting P. vivax
infections, but has low sensitivity [15]. The provincial and
district health ofﬁces provided the training and supervision,
and SMRU performed the laboratory quality control. In
addition to the 100 village workers employed in the MP, ten
administrative staff were hired for data entry and programme
management. By October 2001, the new structures (MP and
mobile teams) represented an 80% increase in the number of
malaria diagnosis and treatment facilities in the province
compared to that before the implementation of TMI.
Patients presenting with symptoms of malaria were offered
a rapid diagnostic test. Those with a positive test were treated
immediately according to the national protocol described
previously (MAS2).
Messages and posters advertising the location of the MPs
and the identity of the MP workers were added during the
second half of 2002 in all villages, and information campaigns
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Burmese, and Karen) were conducted among villagers and
migrant workers. All other activities usually run by the
Malaria Control Programme (bed net distribution and indoor
insecticide spraying) continued unchanged.
Despite the withdrawal of ﬁnancial support for the TMI
project in September 2002, all health centres continued to
provide malaria diagnosis and treatment. Most of the MPs
located in villages of TSY, UMP, and PP districts remained
operational,offeringdiagnosisandtreatmentmainlyduringthe
two malaria peak seasons, as did the Mae Ramat mobile team.
Treatment protocols in the Karen refugee camps remained
unchanged, and indoor-residual spraying with 5% deltameth-
rin was done once during the TMI period (March 2002), but
not the year post-TMI.
Malaria Cases Detection and Recording
Demographic characteristics, type of malaria test and its
result, and treatment received were recorded for each person
visiting a conventional health facility (health centres, health
posts, malaria clinics), an MP in the villages, or a mobile
service. Information on patients seeking care in hospitals was
computerized by hospital clerks and then categorized as
inpatient or outpatient. In all structures, a Thai citizen with
ID card was recorded as Thai, all others were recorded as FN.
A patient presenting twice for illness with the same malaria
species within 1 mo was considered a treatment failure rather
than a new infection because of the low incidence of malaria
in the region.
Mid-year population estimates of Thai citizens by district
were obtained from the provincial statistics ofﬁce and
provided the denominators for measuring the crude malaria
incidence per 1,000 inhabitants. Malaria morbidity was
represented as the annual malaria incidence per 1,000
persons and was calculated as the total number of malaria
cases reported in a year (or as a yearly average of the pre-TMI
period) and divided by the mid-year population of the same
period. Results were recorded by malaria species and by
district.
Pregnant Women Cohort Studies
In the Karen camps (since 1986), weekly antenatal-clinic
consultations have been available for all pregnant women. A
thick and a thin malaria smear were done at each
consultation. Annual incidence rates were calculated for P.
falciparum and for P. vivax separately. Only the ﬁrst episode of
malaria of each species during the pregnancy was counted to
calculate the number of new malaria episodes per pregnant
woman-year at risk over a 1-y period.
Cross-Sectional Surveys
To detect relative changes in the transmission of the two
species, cross-sectional surveys in villages and migrant
communities (Burmese workers, with or without their family,
living in settlements on Thai soil) were conducted during the
rainy season in 2002 using microscopy, to calculate the ratio
P. falciparum/P. vivax. Survey sites were chosen in an open
(nonrandomised) selection to represent each of the district
characteristics (ethnic groups, distance to the health struc-
tures, transport, and known malaria transmission). The cases
detected during the surveys were not included in the
calculation of the annual malaria incidence.
In Vivo Studies of Drug Efficacy
The efﬁcacy of meﬂoquine and artesunate given as MAS3
for the treatment of patients with uncomplicated P. falciparum
malaria conﬁrmed microscopically has been regularly moni-
tored in the area, since the introduction of this combination
therapy in 1994 in the refugee camps. Brieﬂy, patients
attending the SMRU clinics and treated for P. falciparum
uncomplicated malaria who gave their written consent were
followed for 6 wk, daily until resolution of their parasitaemia
and then weekly. Recrudescence between days 5 and 42 was
differentiated from a new infection using parasite genotyping
by PCR [16].
In Vitro Studies
Antimalarial susceptibility of P. falciparum isolates has been
monitored among patients recruited in camps for displaced
people since 1995, and no decline in the susceptibility in vitro
to meﬂoquine has been observed [17]. As the distribution and
use of the combination of meﬂoquine and artesunate as MAS2
was considerably expanded in the province, continuous
monitoring of antimalarial susceptibility to both drugs was
essential. In addition to the continuous routine monitoring in
the camps, in vitro monitoring using a novel double-site
enzyme-linked pLDH immunodetection (commonly termed
DELI) assay [17] was done on isolates from patients over 5 y
old with conﬁrmed P. falciparum and seen during the surveys.
IC50 for artesunate and meﬂoquine were analysed and results
compared with those from the routine monitoring.
Entomological Surveys and Climatic Data
Entomological surveys were conducted in two Thai villages
and in Maela refugee camp. Indoor catching was done in a
small one-room house similar in structure to most of the
Karen houses. In each site, four men (two indoors and two
outdoors) collected the mosquitoes that landed on their
exposed legs. Mosquito collections were done monthly, 4 d/
mo in the Thai villages, and weekly, 5 d/wk in Maela camp.
Mosquito species were identiﬁed on site and the heads of
Anopheline mosquitoes were dissected and analysed for
sporozoite carriage. The presence of P. falciparum circum-
sporozoite antigen, and of P. vivax antigen varieties 210 and
247, were detected by ELISA [18,19].
Monthly climatic conditions (rainfall, mean temperature,
and humidity) were obtained from MS and UMP meteorolog-
ical stations and from the TSY unit for the period 1996–2003.
Those data provided annual trends and seasonal variations.
Ethical Approval
The TMI project was approved by the Thai Ministry of
Public Health. The cross-sectional surveys and the in vitro
drug susceptibility testing were approved by the Ethical
Committee of the Faculty of Tropical Medicine at Mahidol
University, Bangkok. All drugs studies conducted by the
SMRU have been approved by the Ethics Committee of the
Faculty of Tropical Medicine, Mahidol University, the Karen
Refugee Committee, and the Oxford Tropical Medicine
Research Ethics Committee. Participation in all studies and
surveys was entirely voluntary and participants could with-
draw from the study/survey at any time.
Statistical Analysis
Data were analysed using SPSS 10.0 software for Windows
(SPSS, Chicago, Illinois, United States). Proportions were
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2 or by Fisher’s exact test. Normally distributed
continuous data were compared using t-tests and data not
normally distributed by the Mann-Whitney U test. PCR-
adjusted cure rates were calculated using Kaplan-Meier
survival analysis with log rank test for signiﬁcance. In vitro
concentration-response data were analysed by a nonlinear
regression function to determine the IC50 expressed in nM/l.
Results
Population Changes
The Thai Citizen population of the ﬁve districts increased
from 258,529 in mid-year 1996 to 300,396 in 2003 with an
annual population growth of 2%. The total FN population
was stable and estimated at 150,000. The refugee population
ﬂuctuated because of armed attacks until October 1999, at
which time only three camps remained open, and was
estimated at 61,000 at mid-year 2000, increasing to 65,000
during the TMI period, and 63,400 the following year.
Malaria Cases in the Five Districts (Thai Citizens and
Foreign Nationals)
Between 1996 and 2001 (pre-TMI period), the public health
services reported an average of 67,113 malaria cases per year,
with little year-to-year variation. Overall, twice as many P.
falciparum malaria cases were seen per year among FN than in
the Thai population (mean 24,803, range 20,758–30,023
among FN versus 13,280, range 11,789–16,551 among Thais),
giving an estimated annual incidence three times higher in
FN than in Thais. P. vivax malaria was less common than P.
falciparum in both groups, with on average 10,934 (range
8,104–12,915) cases per year in Thais versus 18,058 (range
15,588–20,573) in FNs (Table 1).
During the TMI period (October 2001–September 2002),
the public services diagnosed 45,313 conﬁrmed malaria cases,
of which 25,159 were P. falciparum malaria cases, i.e., a 34%
(95% CI, 33.5–34.4) reduction when compared to the pre-TMI
period. The reduction was seen in both Thais and FN: from
13,280 to 10,460 cases (a reduction of 21.2%; 95% CI, 20.5–
21.9) and from 24,803 to 14,699 cases (a reduction of 40.7%;
95% CI, 40.1–41.4), respectively.
In the year following the intervention (October 2002-
September 2003), there was a further 29.9% (95% CI, 29.4–
30.5) overall reduction in P. falciparum cases. This was
signiﬁcantly greater in Thais than in FN: from 10,460 to
5,794 cases (a reduction of 44.6%; 95% CI, 43.7–45.6) and
from 14,699 to 11,834 (a reduction of 19.5%; 95% CI, 18.9–
20.1) respectively (p , 0.001) and was reﬂected in the decrease
in the estimated malaria incidence (Table 1).
P. vivax malaria cases during and following the TMI period
could not be compared accurately, because the Paracheck
rapid test only detects P. falciparum.
The number of hospital admissions of all causes was
reliably recorded only in Mae Sot hospital and was stable
throughout the three time-periods. By contrast, there was a
marked decrease in the number of admissions due to malaria
(Table 1). The number of hospitalised cases continued to
decrease during the year post-TMI in all but two district
hospitals (TSY and MRM), where it increased substantially,
due to an inﬂux of imported cases from Myanmar. Likewise,
the total number of hospital deaths from all causes was stable
but there was a 51.5% (95% CI, 39.0–63.9) reduction in
malaria-related deaths (Table 1).
In the Karen displaced population a signiﬁcant decrease in
malaria incidence also occurred, although it was less marked
Table 1. Malaria Annual Rates, Incidences, and Deaths in Thai and FN Populations
Category Group Pre-TMI
Period
a
TMI
Period
Post-TMI
Period
Population Total 425,764 447,377 450,396
Thai 275,764 297,377 300,396
FN 150,000 150,000 150,000
Consultations
b All 458,124 483,800 388,249
Malaria cases (positivity rate) Total 67,113 (14.7%) 45,313 (9.4%) 32,374 (8.3%)
Malaria incidence/1,000 persons (95% CI) All 157.6 (156.5–158.7) 101.3 (100.4–102.2) 71.9 (71.1–72.6)
Thai 87.8 (86.8–88.9) 62.2 (61.4–63.1) 36.1 (33.4–36.8)
FN 285.9 (283.6–288.2) 178.7 (176.8–180.7) 143.6 (141.8–145.3)
P. falciparum incidence/1,000 persons (95% CI) Thai 48.2 (47.4–49.0) 35.2 (34.5–35.8) 19.3 (18.8–19.8)
FN 165.4 (163.5–167.3) 98.0 (96.5–99.5) 78.9 (77.5–80.3)
P. vivax incidence/1,000 persons (95% CI) Thai 39.6 (38.9–40.4) NA
c NA
c
FN 120.4 (118.7–122.0) NA
c NA
c
Mae Sot Hospital Admissions
d All causes 17,659 17,734 17,904
Malaria cases hospitalised Five districts 4,140 2,549 2,537
P. falciparum cases
and mixed infections
2,824 1,715 1,700
P. vivax cases 1,002 768 799
Unspecified species 314 66 38
Reported deaths All causes 1,142 1,186 1,178
Malaria deaths (in
percent of all deaths)
66 (5.8%) 32 (2.7%) 22 (1.9%)
aHospital records available from October 1998 for four hospitals (MS, MRM, PP, and UMP) and from October 1999 for TSY.
bConsultations with a malaria test result (positive or negative) made in any of the health services providing malaria care.
cP. vivax cases underestimated with the use of rapid diagnosis for PF only during the period TMI and post-TMI.
dMae Sot hospital admissions (all causes) only reporting system reliable for the study period.
DOI: 10.1371/journal.pmed.0030183.t001
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pregnant women cohort, the incidence of P. falciparum and P.
vivax remained low and stable (Table 2). Indeed, since 1997
the falciparum malaria incidence in this cohort has remained
below 0.2 episodes per pregnant-woman-year, after having
fallen from 2.60 in 1986 to 1.28 in 1992 and 0.37 in 1996. This
decrease is a direct consequence of the overall reduction in
transmission of P. falciparum in the camps population
following the deployment of MAS3 [10].
In all three population groups, P. falciparum malaria was
seen at all ages but with a greater predominance of adult
males among patients in the FNs and the refugees than in the
Thai citizen population (Table 3).
Malaria Prevalence in Cross-Sectional Surveys
Between June and October 2002, 43 sites were surveyed.
Overall participation was 80% of the expected population of
villagers and 90% of the FN communities. An additional 760
Burmese persons living in Burmese villages opposite four of
the screening sites were included in the results, and are
further referred to as Burmese villagers. The prevalence and
ratios of P. falciparum and P. vivax in each population category
are presented in Table 4. While P. falciparum was the most
common species before the intervention (Table 1), P. vivax
became the predominant species among villagers and FN
targeted by TMI. This translated into a change in the P.
falciparum to P. vivax ratio from 1.3 prior to TMI to less than 1
during TMI, while P. falciparum remained predominant
among Burmese villagers where no intervention took place
(Table 4). The higher prevalence of parasitaemia in adults
was evident in the FN and the Burmese villagers, and the
percentage of gametocyte carriers was also signiﬁcantly
higher among Burmese villagers compared to migrants and
Thai villagers (p , 0.001). Finally, there was a clear relation
between the prevalence rates and the distance to the
Myanmar border, with the highest prevalence rates found
in migrant communities closest to the border or in Burmese
villagers.
Entomological and Climatic Data
The annual mean humidity, temperature, and rainfall did
not change signiﬁcantly in the area during the study period
(October 1995–September 2003). Surveys in the villages took
place between September 2001 and August 2002, and in
Maela camp between June 2002 and February 2003.
Anopheles minimus, A. maculatus, and A. dirus were the three
main vectors collected in both villages and in the camp.
Anopheles abundance remained unchanged in Maela camp
compared to previous surveys [10], and species were in similar
proportions. In the villages, A. minimus was the predominant
species (80%), with two high peaks, one in the early rainy
season and the other in the early cold season.
Table 2. Malaria Annual Rates, Incidences, and Deaths in Karen-Displaced Populations
Category Period October 1999–
September 2001
a
TMI
Period
Post-TMI
Period
Population 60,964 64,717 63,399
Consultations
b 46,738 41,116 42,697
Malaria cases (positivity rate) 9,793 (21%) 8,086 (20%) 7,941 (19%)
Malaria incidence/1,000 persons (95% CI) 160.6 (157.7–163.6) 124.9 (122.4–127.5) 125.3 (122.7–127.9)
P. falciparum incidence/1,000 persons (95%CI) 87.8 (85.5–90.0) 60.6 (58.8–62.5) 66.4 (64.5–68.4)
P. vivax incidence/1,000 persons (95%CI) 69.4 (67.4–71.4) 62.2 (60.3–64.1) 57.2 (55.4–59.0)
Reported deaths (all causes) 296 295 297
Malaria deaths (percent of all deaths) 9 (3.0%) 0 (0%) 6 (2.0%)
Malaria incidence in Maela pregnant women (95% CI) 0.33 (0.28–0.38) 0.25 (0.21–0.31) 0.32 (0.27–0.37)
P. falciparum incidence in Maela pregnant women (95% CI) 0.18 (0.14 0.22) 0.14 (0.11 0.18) 0.17 (0.14 0.20)
P. vivax incidence in Maela pregnant women (95% CI) 0.19 (0.16 0.24) 0.15 (0.12 0.20) 0.17 (0.14–0.21)
aPolitical instability in the camp population precluded an analysis of the complete pre-TMI period.
bConsultations with a malaria test result (positive or negative) only.
DOI: 10.1371/journal.pmed.0030183.t002
Table 3. Distribution of Malaria Cases by Age and Sex, in Thais, FN, and in Maela Camp (TMI Period)
Group Males Females
,5 y 5–15 y .15 y ,5 y 5–15 y .15 y
Consultations, Thai (n) 5,820 11,470 28,045 5,204 9,990 17,710
PF total cases/total consultations, percent (95% CI) 7.2 (6.5–7.9) 10.6 (10.0–11.1) 9.0 (8.7–9.4) 6.2 (5.6–6.9) 8.8 (8.2–9.3) 7.1 (6.8–7.5)
Consultations, FN (n) 2,483 4,277 15,742 2,113 3,351 10,060
PF total cases/total consultations, percent (95% CI) 11.1 (9.9–12.4) 18.1 (17.0–19.3) 19.9 (19.3–20.5) 12.1 (10.7–13.6) 16.9 (15.6–18.2) 12.9 (12.3–13.6)
Consultations, Maela (n) 322 930 1,147 331 707 874
PF total cases/total consultations, percent (95% CI) 9.6 (6.7–13.5) 11.8 (9.9–14.1) 22.1 (19.7–24.6) 5.7 (3.6–9.0) 7.8 (6.0–10.1) 12.4 (10.3–14.8)
PV total cases/total consultations, percent (95% CI) 25.8 (21.2–31.0) 46.1 (42.9–49.4) 34.4 (31.7–37.3) 23.6 (19.2–28.6) 30.4 (27.1–34.0) 22.8 (20.1–25.7)
PF, P. falciparum; PV, P. vivax.
DOI: 10.1371/journal.pmed.0030183.t003
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toes collected in Maela camp and 5,575 caught in the villages
were analysed by ELISA to detect sporozoite carriage.
Sporozoite rates were low in all sites (0.21% in Thai villages
and 0.23% in Maela camp for P. falciparum, 0.12% and 0.24%
respectively for P. vivax). The annual entomological inocu-
lation rate derived from these results was 0.087 (95% CI,
0.069–0.105) infective bites per person per year for P.
falciparum and 0.092 (95% CI, 0.073–0.118] per year for P.vivax.
In Vivo Studies of Drug Efficacy and In Vitro Susceptibility
Efﬁcacy of the combination of meﬂoquine and artesunate
(as MAS3) prior to the TMI period was 96.2% (95% CI, 93.6–
97.8). During the TMI period, the cure rate assessed at 42 d in
79 patients was also 96.2% (95% CI, 89.4–98.7) and remained
unchanged the year after the TMI period, at 96.1%, (95% CI,
93.4–98.8), in a study involving 210 patients.
Temporal trends in the geometric mean IC50 (nM/l) for
meﬂoquine and artesunate in isolates from primary P.
falciparum infections treated at SMRU clinics are shown in
Figure 2 for the period (1996–2003). There was a signiﬁcant
increase in the in vitro susceptibility over time for artesunate
(Pearson’s correlation coefﬁcient r ¼  0.404; p , 0.001). A
42% (95% CI, 33.0–53.0) increase in susceptibility was also
observed for meﬂoquine between 1996 and 2001, but by 2003
IC50 levels returned to those described in 1996. The mean
IC50 for meﬂoquine and artesunate tested by the DELI assay
in the isolates obtained during the prevalence surveys in 2002
were not signiﬁcantly different from those treated in SMRU
clinics over the same period using the isotopic microtest:
artesunate IC50 given as geometric mean in nM/l (95% CI) was
1.80 (1.50–2.09) with DELI versus 1.85 (1.72–1.96) with
microtest (p . 0.05); meﬂoquine IC50 was 59.06 (44.12–
78.84) versus 69.92 (63.65–76.43) (p . 0.05).
Figure 2. Changes in Drug Sensitivity of P. falciparum Isolates
Isolates from primary infections were collected at SMRU clinics between
1996 and 2003 and assayed for sensitivity to artesunate and mefloquine,
IC50 geometric means given as nM/l (95% CI).
DOI: 10.1371/journal.pmed.0030183.g002
Table 4. P. falciparum and P. vivax Prevalence and Their Ratios, and Gametocyte Prevalence within the Three Population Categories, by
Sex and Age Groups
Population Test Detail Age ,5 y Age 5–15 y Age .15 y
Females Males Females Males Females Males
Thai villagers Individuals tested (n) 714 776 1,724 1,784 2,939 2,347
P. falciparum 0.6 (0.2–1.5) 0.6 (0.2–1.6) 0.4 (0.2–0.9) 1.1 (0.7–1.7) 0.4 (0.2–0.7) 1.7 (1.2–2.3)
P. vivax 1.4 (0.7–2.6) 1.7 (0.9–2.9) 2.0 (1.4–2.8) 2.7 (2.0–3.6) 1.2 (0.8–1.7) 2.3 (1.7–3.0)
Gameto PF 0.1 (0.0–0.9) 0.1 (0.0–0.8) 0.0 (0.0–0.3) 0.3 (0.1–0.8) 0.2 (0.1–0.5) 0.4 (0.2–0.8)
Gameto PV 0.3 (0.1–1.1) 0.3 (0.0–1.0) 0.4 (0.2–0.9) 0.5 (0.3–1.0) 0.2 (0.1–0.5) 0.4 (0.2–0.8)
Ratio PF/PV 0.4/1 0.4/1 0.2/1 0.4/1 0.3/1 0.8/1
Foreign nationals Individuals tested (n) 176 179 245 302 1,142 1,502
P. falciparum 0.6 (0.0–3.6) 1.7 (0.4–4.3) 3.3 (1.5–6.6) 2.6 (1.2–5.4) 1.0 (0.5–1.8) 3.4 (2.6–4.5)
P. vivax 0.6 (0.0–3.6) 1.7 (0.4–5.3) 4.1 (2.1–7.6) 7.0 (4.5–10.6) 3.9 (2.9–5.2) 6.4 (5.2–7.8)
Gameto PF 0.0 (0.0–2.7) 1.1 (0.2–4.4) 1.2 (0.3–3.8) 0.7 (0.1–2.6) 0.3 (0.1–0.8) 0.9 (0.5–1.6)
Gameto PV 0.0 (0.0–2.7) 0.0 (0.0–2.6) 1.2 (0.3–3.8) 1.7 (0.6–4.0) 0.4 (0.2–1.1) 1.1 (0.6–1.8)
Ratio PF/PV 1/1 1/1 0.8/1 0.4/1 0.3/1 0.5/1
Burmese villagers Individuals tested (n) 59 65 90 108 197 184
P. falciparum 6.8 (2.2–17.3) 4.6 (1.2–13.8) 20.0 (12.6–30.0) 18.5 (11.9–27.4) 13.7 (9.4–19.5) 21.2 (15.7–28.0)
P. vivax 6.8 (2.2;  17.3) 9.2 (3.8–19.7) 10.0 (5.0–18.6) 18.5 (11.9–27.4) 7.6 (4.5–12.5) 9.2 (5.6–14.6)
Gameto PF 0.0 (0.0–7.6) 3.1 (0.5–11.6) 6.7 (2.7–14.5) 10.2 (5.4–17.9) 4.6 (2.3–8.8) 5.4 (2.8–10.1)
Gameto PV 1.7 (0.1–10.3) 3.1 (0.5–11.6) 5.6 (2.1–13.1) 3.7 (1.2–9.8) 1.0 (0.2–4.0) 2.7 (1.0–6.6)
Ratio PF/PV 1/1 0.5/1 2/1 1/1 1.8/1 2.3/1
Prevalence and gametocyte data are given as percents (95% CI).
Gameto, gametocytes; PF, P. falciparum; PV, P. vivax.
DOI: 10.1371/journal.pmed.0030183.t004
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The beneﬁcial effects of the strategy of ED and the 3-d
regimen of ACT implemented in 1994 in the Karen refugee
camps and described previously, have persisted for over 10 y.
The incidence of P. falciparum malaria cases has decreased
continuously in all refugee camps, including those situated in
adjacent provinces, with a concomitant reduction in P.
falciparum-related morbidity and mortality. This was partic-
ularly evident in the less mobile segments of the population,
e.g., pregnant women.
In this project, we assessed the implementation of the same
strategy of rapid diagnosis and treatment with ACT in a much
(seven times) larger population living adjacent to the
Burmese border in Tak province.
During the TMI project, the overall number of consulta-
tions increased only slightly despite an increased diagnostic
capacity, probably because of the transfer of consultations
from the malaria clinics to the newly created village-based
MPs. Changes in diagnostic tools from microscopy to a rapid
test (that detects P. falciparum only) underestimated the
number of P. vivax cases. Nevertheless, the reduction by one-
third in the totalnumber of falciparum malaria cases observed
in the Thai population during the TMI project was sustained a
year later, and these results are consistent with a reduction in
the number of hospital admissions for P. falciparum. This
decrease in falciparum malaria is further conﬁrmed by the
results obtained during the surveys in the villages, showing a
change to predominance of P. vivax species and very low rates
of gametocyte carriage. The predominance of P. vivax malaria,
the changes in P. falciparum prevalence, and low gametocyte
rates conﬁrm the reduction of P. falciparum burden in this
population. The overall reduction in falciparum malaria cases
in the Thai population (a reduction of 56.4%; 95% CI, 55.5–
57.2) was more marked than that observed in FN, and is
probably explained by better access and coverage for
diagnosis and treatment in the Thai population. Indeed, the
proximity of a large reservoir of malaria across the border in
Burma and considerable cross-border population movement
presumably explain why the impact of this initiative was less
than observed previously in relatively contained refugee
camps. These factors also explain the plateau observed in
the number of hospital cases during the post-TMI period, as a
result of an increase in cross-border cases in two of the ﬁve
districts (TSY and MRM). In order to obtain the desired
impact, coverage must be sufﬁcient. In this project, 80% of all
villages had access to a rapid diagnosis and prompt treatment
with ACT, while in the FN population this proportion was
closer to 50%. Improved malaria control in the adjacent
region will be needed to reduce these ﬁgures much further. An
additional factor, which may have limited the impact, is the
use of a 2-d artesunate regimen in combination with
meﬂoquine (i.e., MAS2). This treatment has a lower efﬁcacy
than the generally recommended 3-d regimen, and concerns
have been expressed about the higher meﬂoquine pressure it
exerts on the parasite populations [20].
In the refugee camp population, where the ED and
treatment with ACT were deployed in 1994, we expected
the impact of the TMI intervention to be less noticeable.
Indeed, the rate of infective bites per person for P. falciparum
is now as low as one every 10 y. But movement of people in
and out from the camp perimeter (where transmission is
higher) explains why patients are still presenting with malaria
in the camp clinics and indicates that transmission is not
completely interrupted, especially in the forested fringes
where vectors are more abundant.
The large-scale deployment of the MAS has not modiﬁed
the efﬁcacy of the treatment, which remains extremely high,
and there is no in vitro change in susceptibility to either drug,
although there was a shift of the meﬂoquine IC50 in 2003 back
to the values of 1996. This is of concern and could be related
to the use of unprotected meﬂoquine in the area, as well as to
the less effective regimen (using 2 d of artesunate, MAS2)
deployed by the Thai Ministry of Health [20,21].
During the 2 y of this project we were unable to collect
information on adverse effects of the treatment. However we
have conducted studies in thousands of patients in this area
and consistently found that the MAS3 regimen was well
tolerated [22]. We had no reports of patient complaints
regarding treatment. Indeed, the rapidity of action following
antimalarial treatment with concomitant reduction of symp-
toms was generally recognised by the population and
encouraged treatment-seeking behaviour.
The decrease in malaria morbidity observed during, and
sustained 1 y after the TMI project, the persistence of high
cure rates of the combination therapy 10 y after its ﬁrst
introduction in the province, the persistently low sporozoite
rate, and the rapid acceptance of newly established MPs, all
indicate that it is feasible to extend early malaria diagnosis
and provide adequate treatment even to remote commun-
ities. The impact of this intervention was seen rapidly (within
a year of introduction) in this area of low and seasonal
transmission. We were not in a position to perform a cost-
beneﬁt analysis of the TMI project, but the public health
beneﬁts were evident given the large reductions in morbidity
and mortality observed. These results give further support to
the large-scale use of ED and prompt treatment with ACT, a
strategy that has shown similar results in KwaZulu-Natal [23]
and has now been recommended in all endemic regions to
circumvent the spread of P. falciparum drug resistance and to
reduce the impact of malaria [13].
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Editors’ Summary
Background. Malaria kills about a million people worldwide every year.
Most of these deaths are in children. One of the most serious problems
in the battle against malaria is that the parasites that cause the disease
are able to change and become resistant to the drugs used to treat it.
Widespread drug resistance in the parasite that causes the most serious
type of malaria, Plasmodium falciparum, is of particular concern.
Although Africa is the part of the world with the greatest number of
malaria cases, the problem of drug resistance is most severe in Southeast
Asia; the parasite even has some resistance to drugs introduced just a
few years ago. A new drug, artemisinin, is now the most effective
treatment available. So far, there seems to be no resistance to
artemisinin. It is recommended that artemisinin should be given as a
pill that also contains one of the older drugs. It is thought that this
approach will both slow down the development of resistance to the
older drug and delay the appearance of artemisinin resistance. Several
research projects have shown encouraging results with this combined
form of drug treatment.
Along the Thai-Burmese border there are a number of camps for
displaced people (refugees). In a malaria programme for people in the
camps, efforts were made to diagnose cases early, and people found to
have malaria were then treated with a combination pill, containing
artesunate (a derivative of artemisinin) and another drug, mefloquine. A
study of this programme found that it made a big reduction in the
number of cases of the most serious form of malaria, and suppressed the
advance of resistance to mefloquine.
Why Was This Study Done? It was decided to introduce the same
malaria strategy for all the estimated 450,000 people living in five border
districts of the remote Tak province in northwestern Thailand. It was
necessary for the impact of this larger programme to be studied to see
whether this new approach to malaria control was effective in a remote
area—not just in the particular circumstances of the camps, but on a
wider scale.
What Did the Researchers Do and Find? Village volunteers were
trained to identify cases early, using rapid diagnostic tests. Health
facilities were improved and increased in number, so that the combined
treatment could be given to those who needed it. The researchers
conducted surveys of malaria cases before, during, and after the
programme. They recorded the type of malaria test used and the result,
and the treatment each person received, whether they were treated at
health centres, at village health posts, or by mobile teams. They found
that cases of malaria caused by P. falciparum fell by around a third. There
was no change in the number of cases caused by the other malaria
parasite common in the area, P. vivax. The malaria death rate was halved.
What Do These Findings Mean? The reduction in the number of deaths
shows that the new approach to treatment is more effective, and the
drop in the number of cases shows that the transmission of malaria was
also reduced. This means that, even in a remote area, a programme that
involves both improved diagnosis and the combined artesunate-
mefloquine treatment can have major benefits for the people living
there. This is important not just for Thailand but also for other parts of
the world where malaria is a problem.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030183.
  The Global Malaria Programme of the World Health Organization has a
Web site with information about the disease and the global efforts to
fight it; the site also has links to other organizations and to useful
publications
  The US Centers for Disease Control and Prevention has Web pages on
malaria
  MedlinePlus brings together authoritative information from the US
National Library of Medicine, National Institutes of Health, and other
government agencies and health-related organizations; MedlinePlus
has information specifically on malaria
  Thailand’s Ministry of Public Health has a Web site that includes
information on malaria and malaria control in the country
  The organization that spearheads the research described in this article
is the Shoklo Malaria Research Unit
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